Strategically Accelerate COVID-19 Diagnostics From Development to Market
Since the emergence of COVID-19, many diagnostic and therapeutic developers have pivoted their programs to COVID-19. Many of these programs have been delayed or derailed because of unforeseen challenges. In this article our experts explored real-world examples from their participation in multiple COVID-19 research studies to help diagnostic developers anticipate pitfalls, mitigate risk, and accelerate development.